New US law applies 'sunshine' to physician payments and gifts from drug, device industries

The article reports on a new U.S. law that requires pharmaceutical industries and biologic firms to disclose billions of dollars of payments and in-kinds to physicians and researchers totaling 100 dollars a year or more. It states that the law was incorporated by the U.S. Congress and President Barack Obama to let patients and the public know several financial ties between physicians and the pharmaceutical industries. It says that companies should start collecting the information in 2012.

ACCESSION #

52226845

Related Articles

The article discusses the role of pharmacists and veterinarians in identifying drug shortages and protocols to minimize drug-related adverse events. As reported, a severe shortage of prescription drugs, including injectable anesthetic drugs, chemotherapy agents and antimicrobial drugs, is...

The author discusses the cost of injustice in the U.S., and the effort of President Barack Obama and Attorney General Eric Holder to reform the drug sentencing laws which reduce the discrepancy between crack and powdered cocaine.

The article presents a memorandum which offers a strategic and operational assessment of drugs and crime in Mexico. It is based on the first three-day meeting of the International Forum of Intelligence and Security Specialists which is an Advisory Body to the Mexican Federal Law Enforcement...

The article offers news briefs in the Navajo region. The 2009 Omnibus Spending Bill, signed by U.S. President Barack Obama, will benefit many projects in New Mexico, including $1.9 million for the Navajo Electrification Project and $2 million for Navajo Technical College. Governor Bill...

The article reports on the issue concerning the speculation on the legalization of marijuana by U.S. President Barack Obama's administration. It reveals that marijuana has been found to be safer compared to heroin and alcoholic beverages, such as beer. It states that allowing the trade of...

The article discusses the issues surrounding the transparency theme demanded by President Barack Obama on all federal agencies, especially in healthcare reform efforts, in the U.S. As part of the transparency initiative, pharmaceutical companies are required disclosure on drug research,...

The author discusses U.S. President Barack Obama's commutation of low-level, non-violent drug sentences dealing with the draconian sentences received by those imprisoned on drug-related offenses and the need for reforms in the criminal justice system.